Metagenomi, Inc. Hits New 52-Week Low at USD 1.14

Metagenomi, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.14 on June 16, 2026. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 82.3% over the past year, starkly contrasting with the S&P 500's performance of 24.5% during the same period. The company's financial metrics indicate a difficult operating environment, with a return on equity of -54.59% and a debt-to-equity ratio of -0.98. Additionally, Metagenomi has reported negative results for five consecutive quarters, highlighting ongoing struggles. The price-to-book ratio stands at 0.31, suggesting that the stock is trading below its book value. With a market capitalization of USD 50 million, Metagenomi's performance has been underwhelming, as evidenced by a significant increase in raw material costs, which have risen by 104.78% year-over-year. The stock's 52-week high was recorded at USD 3.94, further emphasizing the extent of its decline.